About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
New Treatment Paradigms to Address R/R MM Treatment Gaps
New Treatment Paradigms to Address R/R MM Treatment Gaps
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Immunotherapy for Multiple Myeloma
By
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Adam D. Cohen
By
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Adam D. Cohen
321 views
February 13, 2023
0 Comments
Login to view comments.
Click here to Login
New Treatment Paradigms to Address R/R MM Treatment Gaps
26:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Bispecifics in Multiple Myeloma
Feat.
P. Mangan
14:59
Jeffrey Zonder
Managing Adverse Events of Bispecific Antibodies
30:40
MyCancerHaven
Experts Discuss Updates in Myeloma From ASCO® 2023
Feat.
R. Vij,
L. Costa
06:11
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…
Feat.
A. Varshavsky-Yanovsky
18:11
Fred Hutchinson Cancer Center
Linvo, Tec/Tal, & BiTEs - Oh My! Making Sense of Bispecific Anti…
Feat.
R. Banerjee
06:59
ecancer
ASCO® 2023 Insights: "Teclistamab for R/R MM - Summary of Long-…
Feat.
N. Van De Donk
05:22
PrecisCa
Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Tri…
Feat.
A. Nooka
07:25
ecancer
Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclist…
Feat.
A. Nooka
05:20
Thomas Martin
Health-Related Quality of Life in R/R MM Treated With Teclistamab, a…
12:33
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…
Feat.
K. Patel
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
11:54
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Betting on BCMA in Multiple Myeloma"
Feat.
R. Vij
26:27
Fred Hutchinson Cancer Center
Treatment Considerations and Best Practices for the Use of Bispecifi…
Feat.
A. Cowan
20:19
Total Health
Total Health MDONS 2023: Updates in Hematology
Feat.
L. Mountjoy
33:17
Total Health
2023 Best of Hematology: Multiple Myeloma Updates
Feat.
A. Yee
23:11
Dana-Farber Cancer Institute
Bispecific Antibodies in Multiple Myeloma
Feat.
O. Nadeem
23:36
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
Immunotherapy for Multiple Myeloma
Feat.
A. Cohen
22:15
Current Challenges in Hematology
Efficacy of BCMA-Targeted Therapies in Pretreated Patients With R/R …
Feat.
C. Cerchione
15:14
Philippe Moreau
EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and …
18:18
Thomas Martin
State of the Art & Next Questions: MM
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
15:08
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
New Therapies for Relapsed Myeloma in 2023
Feat.
D. Vogl
